Study to evaluate health care situation and quality of life in patients with registered anti-VEGF treatment in neovascular AMD, diabetic macular edema or retinal vein occlusion

Study to evaluate health care situation and quality of life in patients with registered anti-VEGF treatment in neovascular AMD, diabetic macular edema or retinal vein occlusion - ALBATROS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00010267

Enrollment

5000

Registered

2016-04-08

Start date

2016-01-19

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with neovascular AMD or visual impairment due to diabetic macular edema or visual impairment due to retinal vein occlusion. H34.8 H35.3 H35.8

Interventions

Group 1: Patients with wet age-related macular degeneration, diabetic macular edema or retinal vein occlusion treated with approved anti-VEGF medication will be interviewed at the beginning and end of

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with neovascular AMD or visual impairment due to diabetic macular edema or visual impairment due to retinal vein occlusion treated with registered anti-VEGF

Exclusion criteria

Exclusion criteria: Pre-treated patients with anti-VEGF or steroids

Design outcomes

Primary

Measure	Time frame
Primary endpoint: Visual quality of life compared to historical group measured with Visual Functioning Questionnair-25 (VFQ-25) at the beginning and after 12 month.	—

Secondary

Measure	Time frame
Secondary endpoints: 1. Fear of visual impairment or blindness, need for assistance and care at home measured by using a questionnaire for patient care and satisfaction (BPZ-9) at the beginning and after 12 month 2. Documentation of patient care related information and disease data: Demography, risk factors, visual function, diagnostic, pretreatment with laser and frequency of treatment mit intravitreal anti VEGF drugs at the same time points using a questionnaire for physicians	—

Measure

Time frame

Secondary endpoints: 1. Fear of visual impairment or blindness, need for assistance and care at home measured by using a questionnaire for patient care and satisfaction (BPZ-9) at the beginning and after 12 month 2. Documentation of patient care related information and disease data: Demography, risk factors, visual function, diagnostic, pretreatment with laser and frequency of treatment mit intravitreal anti VEGF drugs at the same time points using a questionnaire for physicians

—

Countries

Germany

Contacts

Public ContactBettina Müller

Novartis Pharma GmbH

bettina.mueller@novartis.com+4991127313157

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026